Section Arrow
MGX.NASDAQ
- Metagenomi
Quotes are at least 15-min delayed:2025/07/21 06:46 EDT
Pre Market
Last
 2.02
+0.03 (+1.51%)
Bid
1.95
Ask
2.03
High 2.02 
Low 2.02 
Volume 50 
Regular Hours
Last
 1.99
-0.14 (-6.57%)
Day High 
2.15 
Prev. Close
2.13 
1-M High
2.47 
Volume 
431.26K 
Bid
1.95
Ask
2.03
Day Low
1.98 
Open
2.14 
1-M Low
1.41 
Market Cap 
79.62M 
Currency USD 
P/E -- 
%Yield -- 
10-SMA 2.06 
20-SMA 1.78 
50-SMA 1.68 
52-W High 5.1 
52-W Low 1.23 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.85/-2.91
Enterprise Value
119.81M
Balance Sheet
Book Value Per Share
5.69
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
52.30M
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TELOTelomir Pharmaceuticals2.28+1.07+88.43%-- 
Pre Market 2 -0.28 -12.28%
SRPTSarepta Therapeutics14.075-7.895-35.94%15.76PE
Pre Market 13.15 -0.925 -6.57%
NCNANuCana plc0.0477+0.0009+1.92%-- 
Pre Market 0.0474 -0.0003 -0.63%
RXRXRecursion Pharmaceuticals5.84+0.32+5.80%-- 
Pre Market 6.24 +0.4 +6.85%
MEIPMEI Pharma5.92+1.42+31.56%1.09PE
Pre Market 6.06 +0.14 +2.36%
Quotes are at least 15-min delayed:2025/07/21 06:46 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Metagenomi Inc is a genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived genome editing toolbox. The genome editing toolbox includes systems for making small edits such as programmable nucleases, base editors, small RNA-mediated integration systems (RIGS), as well as large gene integration systems including large template RIGS and CRISPR-associated transposases (CASTs). The company is focused on its vivo gene editing for its wholly-owned pipeline while pursuing technology out licensing for ex vivo cell therapy. Its pipeline includes product candidates aimed at addressing disorders like Hemophilia A (through MGX-001), Refractory Hypertension, Cardiovascular diseases, and Wilson's disease, among others.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.